| Active substance | apremilast |
| Holder | Amgen |
| Status | closed |
| Indication | Treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy. The patient has received prior treatment with a topical therapy AND with colchicine. The patient has shown to be resistant or intolerant to colchicine or has a documented contraindication against colchicine. |
| Public documents | Approbation |
| Information for the patient | |
| Informed Consent | |
| Last update | 31/08/2022 |